Infliximab therapy in an infant with Netherton syndrome. Issue 3 (22nd April 2021)

• Record Type: Journal Article
• Authors: Cicek, Fatih; Cekic, Sukru; Kilic, Sara Sebnem
• Is Part Of: Pediatric dermatology. Volume 38:Issue 3(2021)
• Page Start: 714
• Page End: 716
• Publication Date: 2021-04-22
• Subjects: childhood -- ichthyosis -- ınfliximab -- Netherton Syndrome -- tumor necrosis factor‐a; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.14590
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: We present a patient with Netherton syndrome and severe skin manifestations treated with infliximab. By 6 months of age, the child had intractable pruritus, scaling, dry skin, and generalized eczematous lesions resistant to conventional therapies for atopic dermatitis. Clinical improvement was observed following the third infusion of infliximab, and by 12 months of age, the skin lesions completely resolved. Infliximab is a promising option for the management of skin inflammation in Netherton syndrome, even in infants.